Кафедра нервових хвороб

Постійне посилання на фонд

https://repository.pdmu.edu.ua/handle/123456789/30

Переглянути

Перегляд Кафедра нервових хвороб за Автор "Ali, Omar"

Зараз показуємо 1 - 1 з 1
  • Ескіз недоступний
    Документ
    Targeting oxidative stress mechanisms to treat Alzheimer's and Parkinson's disease: a critical review
    (Hindawi, 2022) Aborode, Abdullahi Tunde; Pustake, Manas; Awuah, Wireko Andrew; Alwerdani, Mariam; Shah, Parth; Yarlagadda, Rohan; Ahmad, Shahzaib; Correia, Inês F. Silva; Chandra, Ayush; Nansubug, Esther Patience; Abdul-Rahman, Toufik; Mehta, Aashna; Ali, Omar; Amaka, Shekinah Obinna; Zuñiga, Yves Miel H.; Shkodina, A. D.; Inya, Oko Christian; Shen, Bairong; Alexiou, Athanasios; Шкодіна, Анастасія Дмитрівна
    Neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are becoming more frequent as the age increases. Contemporary therapies provide symptom resolution instead of targeting underlying pathological pathways. Consequently, there is considerable heterogeneity in response to treatment. Research has elucidated multiple potential of pathophysiological mechanisms contributing to neurodegenerative conditions, among which oxidative stress pathways appear to be suitable drug targets. The oxidative stress pathway has given rise to numerous novel pharmacological therapies that may provide a new avenue for neurodegenerative diseases. For example, SKQ (plastoquinone), MitoVitE, vitamin E, SOD mimic, MitoTEMPO (SOD mimetic), and bioactive molecules like curcumin and vitamin C have indeed been examined. To better understand how oxidative stress contributes to neurodegenerative diseases (such as Alzheimer’s and Parkinson’s), we analyzed the medicinal qualities of medicines that target markers in the cellular oxidative pathways. The specific pathway by which mitochondrial dysfunction causes neurodegeneration will require more investigation. An animal study should be carried out on medications that tackle cellular redox mechanisms but are not currently licensed for use in the management of neurodegenerative conditions.